Recent research re. relevance of VAF: MPN Hub... - MPN Voice

MPN Voice

10,759 members14,920 posts

Recent research re. relevance of VAF

hunter5582 profile image
1 Reply

MPN Hub summary Impact of mutated JAK2 allele burden on the outcomes in PV and ET of a recent article by Guglielmelli et al.

durable molecular response (DMR)

complete clinical and hematological response (CCHR)

"Increased DMR was correlated with longer duration of CCHR, reduced progression to myelofibrosis, and increased rates of myelofibrosis-free, event-free, and progression-free survival.

Factors predicting DMR and reduced progression to myelofibrosis included a baseline JAK2 VAF <50% and a VAF reduction ≥35% after 2 years of treatment.

The findings underscore the significance of targeted molecular response in managing myeloproliferative neoplasms, advocating for personalized treatment strategies based on JAK2 VAF dynamics." mpn-hub.com/medical-informa...

Directly from the Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia article abstract.

molecular response (MR)

"Overall, these findings support the clinical value of achieving profound, durable MR and its consideration as surrogate endpoint in future clinical trials." onlinelibrary.wiley.com/doi...

Very interesting and relevant finding.

Written by
hunter5582 profile image
hunter5582
To view profiles and participate in discussions please or .
Read more about...
1 Reply
Wewo01 profile image
Wewo01

Thanks, Hunter!

Not what you're looking for?

You may also like...

Outcomes of JAK2 V617F-positive polycythemia vera and ET according to the JAK2 V617F allele burden

« JAK2 V617F allele burdens were positively correlated with white blood cell counts, hemoglobin...

Notes on Updates and latest research from the ASH annual meeting.

MAZCD posted a good broadcast on "updates and latest research from the ASH annual meeting." I took...

JAK2V617F allele burden in polycythemia vera: burden of proof

« The JAK2V617F variant allele frequency (VAF) is a key determinant of outcomes in PV, including...

Molecular Response vs progression, Rux

A long term study looked at molecular response (MR) vs progression for PV and ET. It was for Rux...

JAK2 V617F Allele Burden and Thrombotic Events in Patients w/ JAK2 V617F Positive PCV/ET @ High Risk of Thrombosis

Background: The goal of therapy of polycythemia vera (PV) and essential thrombocythemia (ET)...